Navigation Links
Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain
Date:9/23/2011

STAMFORD, Conn., Sept. 23, 2011 /PRNewswire/ -- Butrans® (Buprenorphine) Transdermal System CIII 20 mcg/hour provided significantly lower "average pain over the last 24 hours" scores compared to Butrans 5 mcg/hour when used in opioid-experienced patients with moderate-to-severe chronic low back pain, according to a pivotal Phase 3 clinical study published in the online, August issue of The Journal of Pain.

(Logo: http://photos.prnewswire.com/prnh/20100921/NY67262)

"The publication of this data provides important information to healthcare professionals about the role of Butrans for the management of moderate-to-severe chronic pain in patients requiring a continuous around-the-clock opioid analgesic for an extended period of time," said Deborah Steiner, MD, MS, medical director at Purdue Pharma L.P.

The Butrans Transdermal System, approved by the U.S. Food and Drug Administration (FDA) in June 2010, is indicated for the management of moderate-to-severe chronic pain in patients requiring an around-the-clock opioid analgesic for an extended period of time.  Butrans is the first transdermal system approved in the United States that delivers continuous release of the active ingredient, buprenorphine, for seven days.

Butrans is a Schedule III opioid prescription medication and can be abused in a manner similar to other opioid agonists, legal or illicit.  Working with the FDA, Purdue Pharma L.P. has developed a Risk Evaluation and Mitigation Strategy (REMS) for Butrans that includes a Medication Guide, Elements to Assure Safe Use, such as healthcare providers training, and a timetable for submitting assessments of the REMS.  This information is available at www.Butransrems.com.

Butrans is contraindicated in patients who have significant respiratory depress
'/>"/>

SOURCE Purdue Pharma L.P.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. AIMs Program for Improving Echocardiography Appropriateness Yields Impressive Results
2. Misonix Reports Fourth Quarter and Year-End Fiscal 2011 Financial Results
3. Accuray Announces Results for Fourth Quarter and Fiscal Year 2011
4. Misonix Schedules Fourth Quarter and Year-End Fiscal 2011 Financial Results Conference Call; September 20, 2011 at 4:30 p.m. Eastern
5. Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD
6. Pro-Dex, Inc. Announces Fiscal 2011 Fourth Quarter and Full-Year Results
7. Intarcia Presents Compelling 48-week Results for ITCA 650 - Data Underlines the Promise to Become the First Injection-free GLP-1 Therapy at the 47th Annual EASD Meeting in Lisbon
8. ResMed Announces Conference Call and Webcast to Discuss First Quarter 2012 Results
9. Champions Oncology Reports Fiscal 2012 First Quarter Financial Results
10. Innocoll Announces Top-line Results from its Phase 2 Clinical Trial Investigating XaraColl® for the Management of Post-operative Pain and Receives "Notice of Allowability" for XaraColl U.S. Patent Application
11. Positive Results From Avanafil Phase 3 Study in Diabetics Presented at the 47th EASD Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... ANN ARBOR, Mich. , Sept. 18, 2014 /PRNewswire-USNewswire/ ... Medical Research will allow the University of Michigan to ... The Glenn Center for Aging Research ... growing evidence that drugs can slow the effects of ... to unlock mechanisms of aging that can help develop ...
(Date:9/18/2014)... , Sept. 18, 2014   3D Systems   ... the Simbionix RobotiX Mentor™ , a new robotic surgery ... the first time at the ERUS exhibition in ... (booth #7). Robotic-assisted minimally invasive surgery represents a ... means the needs for training for robotic surgery has increased, ...
(Date:9/18/2014)... , Sept. 18, 2014  Halozyme Therapeutics, Inc. ... the U.S. Food and Drug Administration (FDA) has ... dosing of PEGPH20 in SWOG,s ongoing Phase 1b/2 ... evaluate Halozyme,s investigational drug PEGPH20 (PEGylated Recombinant Human ... in patients with metastatic pancreatic adenocarcinoma.  The study ...
Breaking Medicine Technology:$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 33D Systems Introduces New Simbionix Robotics Training Platform 23D Systems Introduces New Simbionix Robotics Training Platform 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 2SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 4
(Date:9/18/2014)... York, New York (PRWEB) September 18, 2014 ... Xarelto lawsuits ( http://www.xareltolawsuitcenter.com ) currently pending in ... to have all claims filed on behalf of ... to motions filed on September 11th, the defendants ... other claims contained in the lawsuits have no ...
(Date:9/18/2014)... Memorial Cardiac and Vascular Institute ... performing the first ever, adult heart transplant in Broward ... Sharing) approval to launch the adult heart transplant program ... in South Florida. , The skilled cardiac transplant ... Medical Director of the Adult Heart Transplant and Mechanical ...
(Date:9/18/2014)... 18, 2014 (HealthDay News) -- Older people become more ... because the balance of stress hormones during bereavement changes ... people who are grieving are more likely to have ... "During the difficult weeks and months after loss, ... the most abundant type of white blood cell and ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 One of ... air medical transport industry, ShandsCair Flight Program’s ... Helicopters Inc . (AHI) at the Air Medical Transport ... recently delivered and placed into service ShandsCair EC155 and ... will be displayed at AMTC highlight Airbus Helicopters broad, ...
(Date:9/18/2014)... (HealthDay News) -- Daily supplements of selenium or vitamin ... of age-related cataracts among men, a new study indicates. ... both could help prevent cataracts. To investigate this further, ... Medical School in Boston, and his colleagues examined data ... E. The trial was initially designed to study prevention ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 3Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 2Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 3Health News:Memorial Cardiac & Vascular Institute Performs First Adult Heart Transplant in Broward County 4Health News:Grief Can Weigh on Immune System in Older Folks, Study Says 2Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 2Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 3Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 4Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2
... new study researchers say they found that chest pain ... elderly patients treated // with angioplasty and those on ... these benefits earlier. ,Patients treated with surgery ... treated patients required more antianginal drugs throughout the study. ...
... most common symptom in patients with plaque build-up in ... medication // nifedipine (Adalat or Procardia) may be safe ... angina symptoms and prolongs heart-problem-and-procedure-free survival. ,For ... nifedipine gastrointestinal therapeutic system or a placebo. GITS modifies ...
... solvents and cleaning products at home may increase the ... findings from a recent study. Researchers found the levels ... the homes of children with asthma. Volatile organic compounds ... polishes, room fresheners, fitted carpets, and cigarette smoke. ...
... Researchers from the University of Florida College of Medicine ... for hypertension // in older patients. Researchers say most ... blood pressure, so this study was set up to ... study found patients had similar outcomes when they took ...
... frustrated when patients ask them what type of bed is ... done// on this issue to support their answers. Therefore, researchers ... a firm vs. a medium-firm mattress when it comes to ... had their own bed mattresses replaced with either a firm ...
... degenerative joint disease and one of the oldest and ... joint’s cartilage breaks down and the bones rub against ... ,An international, multi-center study shows an effective treatment for ... Prexige. The drug was found to reduces gastric complications ...
Cached Medicine News:
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: